openPR Logo
Press release

EU TEAM DEVELOPS NEW ALZHEIMER'S VACCINE FROM AUSTRIA

12-11-2006 04:35 PM CET | Health & Medicine

Press release from: PR&D - Public Relations for Research & Development

/ PR Agency: Public Relations for Research & Development
A recently approved project of the sixth EU Framework Programme – MimoVax – is focussing on a new target for an Alzheimer's vaccine. The project, coordinated by the Austrian company Affiris GmbH, centres on the use of immune reactions to combat previously overlooked forms of the beta-amyloid that cause Alzheimer's disease. It is being run by seven partner organisations from three countries and has received an exceptionally positive response from Brussels – as well as Euro 2.4 million in financial support.

The signing of the contract yesterday signalled the start of the active phase of the EU MimoVax project. The project is part of the sixth EU Framework Programme and is seeking to develop an Alzheimer's vaccine that targets specific types of beta-amyloid, the causative agent of Alzheimer's disease.

Dr. Frank Mattner, Project Manager and CSO of Affiris GmbH, explains, "Alzheimer's is caused by deposits of beta-amyloid peptides. These deposits – also known as plaques – are formed when parts of a human protein detach from the cell membrane of nerve cells and clump together. A high proportion of these peptides, the so called beta-amyloids, consist of 40 or 42 amino acids. The first vaccine developed by Affiris targets precisely these types of peptides and helps to break down the plaques."

MimoVax is now pursuing an additional strategy. The project aims to investigate whether an immune reaction can also be induced against other, rarer, forms of beta-amyloid. Indeed, not all peptides in the plaques consist of 40 or 42 amino acids. Mechanical stress or enzymes can cause some amino acids to break down or can alter their chemical composition. Although these modified peptides are also a suitable point of attack for novel treatment strategies, no relevant development programme has been started to date. MimoVax is now changing this.

It was a technology from Affiris GmbH that proved decisive in securing approval for the project. This technology enables scientists to get round a key problem posed by vaccines against degenerated human proteins such as beta-amyloid – the development of autoimmune reaction. By carefully selecting the correct peptides for the vaccine, Affiris GmbH's mimotope technology enables a precise immune reaction to be implemented against only the degenerated form of the protein, and for this to be done without attacking the natural form. This principle has already been proven in the first vaccine developed by Affiris.

Frank Mattner continues, "The exceptional approval rating the Framework Programme's panel of independent experts gave the MimoVax project – 29 out of a possible 30 points – is, of course, also a great vote of confidence in Affiris' mimotope technology. And, actually, MIG-Fonds in Germany have already invested in this Affiris technology, thereby enabling us to reach the current stage of development for our first Alzheimer's vaccine. This will be used on the first patients in the coming months. Overall, this broad financial support demonstrates wide-ranging confidence in the use of mimotope technology as an efficient strategy for vaccinating against human rogue proteins."

During the MimoVax project, both pre-clinical and the first clinical phases of development for the new vaccine will be carried out over the next three years. Throughout the project, Affiris will be coordinating a group of partners from Austria, Germany and Spain comprising three other industrial companies, two university institutes and a clinic. 20 scientists are working together in this group and will be meeting in Vienna for their first working conference as early as October.

Background: MimoVax – mimotope vaccine – is a specific targeted research project (STREP, Contract Number LSHB-CT-2006-037702) for the development and optimisation of an Alzheimer's vaccine as part of the sixth EU Framework Programme. The aim of the project is to develop a vaccine that attacks modified forms of the beta-amyloid that causes Alzheimer's. New diagnostic methods are also being developed to enable the vaccine's efficacy to be accurately analysed. The MimoVax partners, from Spain, German and Austria, comprise four industrial companies, two university institutes and one clinic. The project will run for three years and is receiving Euro 2.4 million in EU funding. Affiris GmbH in Vienna is responsible for managing the project.

Industry: Affiris GmbH (AT), JSW Research GmbH (AT), piCHEM R&D GmbH (AT), biolution Co & KEG (AT).
Universities: Technische Universität München (DE), Philipps-Universität
Marburg (DE)
Hospitals: EuroEspes Biomedical Research Center (ES)

About AFFiRiS GmbH (as at December 2006):
AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease and atherosclerosis. The company has established platform technologies and registered seven patents. The company employs 20 people on 600 sqm of rented laboratory facilities at the Campus Vienna Biocenter (www.affiris.com).


Contact for Affiris GmbH:
Dr. Frank Mattner
Campus Vienna Biocenter 2
1030 Vienna, Austria
T +43 / 1 / 798 1575 15
E frank.mattner@affiris.com

Vienna, 11th December 2006

Copy Editing & Distribution:
PR&D - Public Relations for Research & Development
Campus Vienna Biocenter 2
1030 Vienna, Austria
T +43 / 1 / 505 70 44
E contact@prd.at

-------------------
Michaela Fritsch
Assistant

PR&D - Public Relations for Research & Development

T +43 1 505 70 44
F +43 1 505 50 83
E fritsch@prd.at

Campus Vienna Biocenter 2
A 1030 Vienna, Austria

http://www.prd.at

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EU TEAM DEVELOPS NEW ALZHEIMER'S VACCINE FROM AUSTRIA here

News-ID: 13635 • Views: 1602

More Releases from PR&D - Public Relations for Research & Development

BALZAN PRIZES 2008: PRIZE WINNERS TO BE ANNOUNCED ON 8 SEPTEMBER
Vienna, 2 September 2008. The International Balzan Foundation will announce the winners of this year’s prestigious Balzan prizes on 8 September 2008 in Milan. The foundation will be awarding the prizes in honour of exceptional research in Preventive Medicine, the Science of Climate Change, the Visual Arts Since 1700 and Moral Philosophy. The prizes, which are each worth one million Swiss Francs, are to be presented on 21 November in
"Wanted - spaceship engine noise" Intelligent sound database developed
St. Poelten, AUSTRIA 26 May 2008 – From 30 May 2008, media producers will be able to access an efficient and easy-to-use new technology that will help them track down the sound effects they need. After two and a half years of development work, the AllThatSounds (ATS) intelligent database for sounds and noises is going online at allthatsounds.net . The database has been designed and developed by a research
EQUAL PAY. BETTER PERFORMANCE. EXPERIMENT REVEALS: STANDARDISED CONTRACTS MAKE E …
Standardised employment contracts based on the \"equal work, equal pay\" principle boost motivation. There is a clear increase in performance levels and market efficiency compared to working conditions based on individually negotiated contracts. This important finding was uncovered by scientists from the University of Innsbruck, Austria, as they analysed results from an economic experiment. The project, supported by the Austrian Science Fund (FWF), has attracted great interest in Austria, as
Vienna: The Human Genome on 6 x 4 cm - Symposium on Molecular Diagnostics
The importance of molecular diagnostics for cancer treatment is set to increase significantly in coming years, according to a symposium held yesterday in Vienna. The reason for organising the symposium was the acquisition of a cutting-edge microarray analyser as part of the EU OVCAD (Ovarian Cancer Diagnosis) project. The device provides what is currently the most sensitive technology for analysing the activity of all human genes and therefore enables the

All 5 Releases


More Releases for Affiris

AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised • Strengthened management team, Günther Staffler appointed as Chief Technology Officer • Noel Barrett appointed as additional member of the supervisory board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016. In
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds a …
Vienna, 23rd June 2009. MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity award competition hosted by the industry magazine Boerse-Express and Junge Industrie. The award recognised the long-standing association between the German venture fund and the Austrian biotechnology company as well as a EUR 430 million deal between AFFiRiS and GSK Biologicals. Last Tuesday MIG Fonds and AFFiRiS AG were awarded first
04-17-2008 | Health & Medicine
Affiris
AFFIRIS DEVELOPS ALZHEIMER'S VACCINE
Vienna, 17. April 2008. The Viennese biotech company Affiris is today taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well. As a result, Affiris is among the leading international centres in the race to develop the first causal immunotherapy for Alzheimer's disease. Due to the dramatic
Affiris Expands Patent Portfolio for Alzheimer’s Therapies
Vienna, 27. February 2008. Affiris GmbH has secured another Europe-wide patent for an innovative method of treating Alzheimer\'s disease. This new blood-cleansing method is similar to dialysis and is designed to reduce the amount of harmful protein deposits in the brain. It is based on the AFFITOME technology established by Affiris, which was patented in October 2007 for an Alzheimer\'s vaccine. The use of this technology to cleanse the blood